Last reviewed · How we verify

NCT05980559

Evaluation of BTX Injections in Treatment of Bruxism

Status unknown Phase 3 Last updated 5 January 2024
What this trial tests

Phase 3 trial testing Xeomin in Bruxism in 12 participants. Status unknown.

Timeline
15 January 2024
Primary endpoint
15 January 2024
15 April 2024

Quick facts

Lead sponsorAlexandria University
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date15 January 2024
Primary completion15 January 2024
Estimated completion15 April 2024

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 20 to 60, any sex, with Bruxism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of this study is to evaluate the effect of botulinum toxin type A (Xeomin®) on patients complaining from bruxism. The study will be a one arm clinical trial. Twelve subjects reporting bruxism irresponsive to conventional treatment modalities will be recruited and will be injected with botulinum toxin A (Xeomin®) in both masseter and temporalis muscles. Pain levels, Electromyographic activity and maximum occlusal force will be recorded in the subjects before injection and at 1 and 3 months after injection to determine the effect of treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Xeomin

Trials testing the same drug.

Other recruiting trials for Bruxism

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05980559.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing